-
-
A new study points out the risk of nonsteroidal anti-inflammatory drug (NSAID) use in patients who have had a myocardial infarction (MI) suggesting that even brief use increases the risk for death and recurrent MI.
-
The FDA has approved linagliptin for the treatment of type 2 diabetes in adults.
-
The FDA has approved two new drugs for the treatment of hepatitis C the first new drugs to be approved in years.
-
Niacin may not be effective in preventing cardiovascular disease.
-
With the advent of new vaccines, the incidence of bacterial meningitis has declined, particularly in children, but the mortality rate has remained the same.
-
Variant Creutzfeldt-Jakob disease usually presents with subtle psychiatric symptoms and there is usually a significant delay in diagnosis.
-
Patients originally on interferon beta-1a in the TRANSFORMS study were re-randomized to either 0.5 or 1.25 mg of fingolimod. There was a reduction in relapse rate and MRI activity in patients that switched to fingolimod without an increase in severe adverse events.
-
-
Biomarkers for Parkinson's disease and related neurodegenerative diseases occur frequently in patients with idiopathic REM sleep behavior disorder. These include impairment of olfactory and color discrimination, and abnormalities in cerebral blood flow.
